Skip to main content
Fig. 1 | Radiation Oncology

Fig. 1

From: Early recovery of leukocyte subsets is associated with favorable progression-free survival in patients with inoperable stage II/III NSCLC after multimodal treatment: a prospective explorative study

Fig. 1

Overview of the study design. Blood samples were collected before (A.1), during and at the end of radio- or concurrent radio-chemo-therapy (RT or cCRT; A.2, A.3, RTend), as well as up to one year after end of therapy (C.1 to C.5). Patients undergoing additional ICI therapy either received Nivolumab (····) concurrent to cCRT or Durvalumab sequential to cCRT (- - -), with continuation for up to one year. PFS assessment started with completion of cCRT (time point RTend). PFS3M refers to PFS until 3 months after RTend, PFS6M is PFS up to 6 months and PFS12 PFS up to 12 months after RTend. Detailed information on the patients’ individual treatment regimen is summarized in Figure S1

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us